AMR: Statement from global medicines regulators on combatting antimicrobial resistance

06-08-2019

AMR: Statement from global medicines regulators on combatting antimicrobial resistance

(Source: ICMRA 2019-08-07)

The International Coalition of Medicines Regulatory Authorities (ICMRA) is committing its support, in collaboration with the World Health Organization (WHO), for the fight against antimicrobial resistance (AMR).

Antimicrobials are essential to the delivery of modern healthcare. The WHO has declared AMR to be one of the top ten threats to global public health. It threatens our ability to treat even the most minor infections, and could seriously compromise surgical procedures and other advanced and life-saving medical interventions. It is a major threat to global public health, economic prosperity and security. Without action, it is estimated that AMR will result in a loss of USD$100 trillion of economic output and 10 million lives worldwide each year by 2050.

It is crucial that we preserve the antimicrobials currently available by preventing infections and by reducing their overuse and misuse, which promotes resistance, while ensuring global access to antimicrobials for those in need. There is also a need for innovative new therapies and technologies to help prevent, diagnose and treat infections.

ICMRA recognizes that AMR is a complex, multi-faceted problem, and is calling for a coordinated, One Health response across all sectors, including public health, animal health, and the environment. Its member medicines regulators from around the globe have united with the WHO to strongly encourage policy makers, industry, academia, healthcare professionals, non-governmental organizations, media organizations, and the public to come together to:

• minimize the emergence and spread of AMR;

• continue advances in antimicrobial surveillance, infection prevention and control, and stewardship;

• prioritize the development of innovative new medicines and other therapeutic products that will help combat AMR, including diagnostics and alternatives to antimicrobials;

• ensure equitable access to antimicrobials across the globe; and

• minimize the release of substances with antimicrobial properties into the environment.

To continue reading this article please go to ICMRA

New Article